Evaluation of the Integrated Management of Childhood Illness guidelines for treatment of intestinal helminth infections among sick children aged 2-4 years in western Kenya

Trans R Soc Trop Med Hyg. 2002 Sep-Oct;96(5):543-8. doi: 10.1016/s0035-9203(02)90435-9.

Abstract

Anthelmintic treatment of sick preschool-age children at health facilities is a potentially effective strategy for intestinal helminth control in this age-group. We conducted a study from July 1998 to February 1999 in western Kenya to determine whether the Integrated Management of Childhood Illness (IMCI) guidelines' clinical assessment can be used to identify helminth-infected children, and to evaluate the nutritional benefit of treating sick children without pallor with an anthelmintic (mebendazole is already part of IMCI treatment for sick children aged 2-4 years with palmar pallor in areas where hookworm and Trichuris trichiura infections are endemic). Sick children aged 2-4 years seen at 3 rural health facilities were clinically evaluated and tested for haemoglobin concentration, malaria parasites, and intestinal helminths. Children without pallor were randomly assigned to receive a single dose of 500 mg of mebendazole or a placebo and re-examined 6 months later. Among the 574 children enrolled, 11% had one or more intestinal helminths. Most infections were of light intensity. Selected clinical signs and symptoms available from the IMCI assessment, including palmar pallor and low weight-for-age, were not associated with helminth infection. Six months after enrollment, no differences in growth of children without pallor were observed between the mebendazole (n = 166) and placebo (n = 181) groups. However, there was a significantly greater mean increase in weight, height, and weight-for-age Z score among the helminth-infected children in the mebendazole group (n = 22) as compared with helminth-infected children in the placebo group (n = 20). We conclude that even lightly infected preschool-age children without palmar pallor benefit from anthelmintic treatment; however, in this study setting of low helminth prevalence and intensity, helminth-infected children could not be identified using the IMCI guidelines. Cost-effectiveness studies are needed to help define helminth prevalence thresholds for routine anthelmintic treatment of sick preschool-age children seen at first-level health facilities.

Publication types

  • Clinical Trial
  • Evaluation Study
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antinematodal Agents / therapeutic use*
  • Ascariasis / drug therapy*
  • Ascariasis / epidemiology
  • Ascaris lumbricoides
  • Body Height
  • Body Weight
  • Child, Preschool
  • Cross-Sectional Studies
  • Diarrhea / etiology
  • Feces / parasitology
  • Fever / etiology
  • Hookworm Infections / drug therapy*
  • Hookworm Infections / epidemiology
  • Humans
  • Kenya / epidemiology
  • Mebendazole / therapeutic use*
  • Practice Guidelines as Topic / standards*
  • Prospective Studies
  • Trichuriasis / drug therapy*
  • Trichuriasis / epidemiology
  • Trichuris

Substances

  • Antinematodal Agents
  • Mebendazole